Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 23, 2026

Prediction: Nvidia Will Become the World's First $15 Trillion Company by 2029

View original at finance.yahoo.com
Prediction: Nvidia Will Become the World's First $15 Trillion Company by 2029 Nvidia(NASDAQ: NVDA) became the first company in the world to achieve a $5 trillion market capitalization in October 2025, fueled by the artificial intelligence (AI)-powered growth in its revenue and earnings in recent years…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Nvidia will become the world's first $15 trillion company within the next three years (by approximately 2029)

    60% confidence
  • Nvidia's GPUs remain relevant and competitive in the AI inference era despite the preference shift toward custom chips

    60% confidence
  • Nvidia's non-GAAP earnings jumped 140% year over year to $1.87 per share in Q1 FY2027, up from 33% EPS growth in the year-ago period

    60% confidence
  • Nvidia anticipates $91 billion in revenue in Q2 FY2027, representing a 95% increase over the year-ago period

    60% confidence
  • An unnamed 'Indispensable Monopoly' company provides critical technology that both Nvidia and Intel require

    60% confidence
  • Hyperscalers and AI companies prefer custom chips in the inference era to reduce compute costs

    60% confidence
  • Nvidia reported 85% year-over-year revenue growth in Q1 FY2027 to $81.6 billion, significantly above the 69% growth in the same quarter last year

    60% confidence
  • GPUs are considered overkill for inference applications because inference workloads require much less computational power than training

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com